Select a medication above to begin.
Brexafemme
ibrexafungerp
Black Box Warnings .
Embryo-Fetal Toxicity Risk
contraindicated in pregnancy because may cause fetal harm based on animal studies; for pts of childbearing potential, verify pregnancy status before tx start; reassess pregnancy status before each dose when used for recurrent vulvovaginal candidiasis incidence reduction; advise pts of childbearing potential to use effective contraception during tx and x4 days after last dose
Adult Dosing .
Dosage forms: TAB: 150 mg
candidiasis, vulvovaginal
- [treatment]
- Dose: 300 mg PO q12h x1 day
- [recurrence reduction]
- Dose: 300 mg PO q12h x1 day; Info: give on same day of mo x6mo
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: TAB: 150 mg
candidiasis, vulvovaginal
- [treatment, postmenarchal females]
- Dose: 300 mg PO q12h x1 day
- [recurrence reduction, postmenarchal females]
- Dose: 300 mg PO q12h x1 day; Info: give on same day of mo x6mo
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined